Basel: Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

As seen in the DESTINY-Breast06 trial, approximately 20-25 percent of hormone receptor (HR)-positive, HER2-negative breast ...

Related questions and participation interest can be emailed to: [email protected] About Breast Cancer and HER2/neu Positivity One in eight U.S. women will develop invasive breast ...

Nintendo has finally revealed the Switch 2 with a video that confirms a number of new features while sparking burning questions for fans to discuss. While pre-announce leaks proved to be pretty ...

Oli Welsh is senior editor, U.K., providing news, analysis, and criticism of film, TV, and games. He has been covering the business & culture of video games for two decades. After many months, if ...

I started with CNET reviewing laptops in 2009. Now I explore wearable tech, VR/AR, tablets, gaming and future/emerging trends in our changing world. Other obsessions include magic, immersive ...

Datroway is approved for HR-positive, HER2-negative breast cancer after prior endocrine and chemotherapy treatments. TROPION-Breast01 trial showed Datroway improved progression-free survival and ...

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for patients with HR-positive, HER2-negative breast cancer. The FDA has approved ...

After seven years on the market, 146 million systems, and more than 1 billion games sold, Nintendo has finally announced the Nintendo Switch 2. The rumor mill was heating up in January, and this ...